58 completed, 19 terminated, 12 recruiting, 7 unknown. 37 Phase 2, 31 Phase 3, 17 Phase 4, 16 Phase 1, 9 Not applicable.
Follow Valganciclovir: new trials by email Literature Review of Valganciclovir trials Research Report on Valganciclovir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II Valganciclovir, Ganciclovir (GCV), Placebo - Cytomegalovirus (CMV), Anterior Uveitis | Phase 2 | Not yet recruiting | University of California, San Francisco | 117 | 2026-11-01 | 2026-08-11 |
| Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection Valganciclovir - Brain Cancer Metastatic, CMV Viremia | Phase 2 | Recruiting | The Methodist Hospital Research Institute | 28 | 2026-07-14 | 2026-08-10 |
| ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse Valganciclovir, Placebo - Cytomegalovirus (CMV) Infection | Phase 2 | Not yet recruiting | Wits Health Consortium (Pty) Ltd | 130 | 2026-02-01 | 2026-01-30 |
| Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients Letermovir, Placebo, Valganciclovir/Ganciclovir - CMV, Lung Transplant Recipient | Phase 4 | Recruiting | University Health Network, Toronto | 40 | 2025-12-24 | 2026-02-17 |
| Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study Valacyclovir (Valtrex), Valganciclovir (Valcyte) - Kidney Transplantation, Cytomegalovirus Infections, EBV Infection | Not applicable | Recruiting | National Taiwan University Hospital | 80 | 2025-11-27 | 2025-12-19 |
| Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant Letermovir, Valganciclovir - CMV Viremia, Heart Transplant Infection | Phase 2 / Phase 3 | Recruiting | Columbia University | 150 | 2025-09-12 | 2026-10-02 |
| EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma Valganciclovir Hydrochloride Tablets, gemcitabine, cisplatin, and PD-1 antibody - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 10 | 2025-08-19 | 2025-08-24 |
| Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients Valganciclovir (Pre-emptive CMV Therapy), Valganciclovir CMV Prophylaxis - Cytomegalovirus (CMV), Kidney Transplant; Complications | Phase 3 | Recruiting | University of California, San Francisco | 360 | 2025-07-22 | 2026-11-02 |
| Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients Letermovir, Valganciclovir - Kidney Transplant | Phase 4 | Recruiting | First Affiliated Hospital Xi'an Jiaotong University | 290 | 2025-05-13 | 2025-12-05 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma RZ-001, VGCV - Glioblastoma | Phase 1 / Phase 2 | Recruiting | Rznomics, Inc. | 43 | 2024-10-08 | 2025-09-05 |
| CMV Immunity Monitoring in Lung Transplant Recipients Cytomegalovirus T Cell Immunity Panel (CMV-TCIP), Donor-Derived Cell-Free DNA (dd-cfDNA) Assay, Valganciclovir - Lung Transplant; Complications | Phase 2 | Recruiting | NYU Langone Health | 50 | 2024-09-13 | 2026-05-29 |
| Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections Letermovir, Valganciclovir, Letermovir placebo - Cytomegalovirus Infection | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 80 | 2024-08-14 | 2026-01-02 |
| Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors GEN2 + Valganciclovir - Solid Tumor, Adult | Phase 1 | Terminated | GenVivo, Inc. | 37 | 2024-03-04 | 2026-03-13 |
| A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers [14C]-Nanatinostat, Nanatinostat (free base) tablets in combination with Valganciclovir, Nanatinostat mesylate tablets in combination with Valganciclovir - Advanced Cancer | Phase 1 | Terminated | Viracta Therapeutics, Inc. | 8 | 2024-02-28 | 2025-01-20 |
| Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients Maribavir, Valganciclovir - Transplant Complication, CMV | Phase 4 | Completed | Medical University of South Carolina | 70 | 2023-11-06 | 2026-04-30 |
| CMV CTLs in Neonates With CMV Infection CMV Cytotoxic T-Lymphocytes, Anti-viral Therapy - Congenital Cytomegaloviral (CMV) Disease | Phase 2 | Recruiting | New York Medical College | 23 | 2023-07-01 | 2026-10-28 |
| Letermovir for CMV Prevention After Lung Transplantation Letermovir, Valganciclovir - Lung Transplant, CMV | Phase 2 | Completed | Fernanda P Silveira, MD, MS | 15 | 2021-12-06 | 2026-04-09 |
| ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION Valganciclovir, Placebo - Major Depressive Disorder | Phase 1 / Phase 2 | Completed | Laureate Institute for Brain Research, Inc. | 20 | 2021-11-23 | 2026-04-21 |
| Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC Nanatinostat, Valganciclovir, Pembrolizumab - Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma | Phase 1 | Terminated | Viracta Therapeutics, Inc. | 26 | 2021-10-08 | 2025-03-12 |
| An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas Nanatinostat in combination with valganciclovir - Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS | Phase 2 | Terminated | Viracta Therapeutics, Inc. | 102 | 2021-05-28 | 2025-07-28 |
Showing 20 of 106. Sign in to see all of them.
Cytomegalovirus Infections (43) · Multiple Acyl Coenzyme A Dehydrogenase Deficiency (9) · Epstein-Barr Virus Infections (6) · HIV Infections (6) · Lymphoproliferative Disorders (4) · Sarcoma, Kaposi (4) · Acquired Immunodeficiency Syndrome (3) · Cytomegalovirus Retinitis (3) · Glioblastoma (3) · Hearing Loss, Sensorineural (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Nasopharyngeal Carcinoma (3) · AIDS-Related Opportunistic Infections (2) · Castleman Disease (2) · Colitis, Ulcerative (2)
Hoffmann-La Roche (11) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · University of California, San Francisco (4) · Viracta Therapeutics, Inc. (4) · Duke University (3) · National Cancer Institute (NCI) (3) · Assistance Publique - Hôpitaux de Paris (2) · Dr. Ann C.T.M. Vossen (2) · Dr. Reddy's Laboratories Limited (2) · First Affiliated Hospital Xi'an Jiaotong University (2) · HemaQuest Pharmaceuticals Inc. (2) · Jazz Pharmaceuticals (2) · Medical University of South Carolina (2) · Shire (2) · University Health Network, Toronto (2)
United States (65) · Spain (16) · Canada (14) · France (12) · United Kingdom (12) · Australia (9) · Germany (9) · Austria (8) · Italy (8) · Mexico (7) · Belgium (5) · Brazil (5) · Taiwan (5) · China (4) · Israel (4)
Darrel P Cohen, MD, PhD (3) · John A Gonzales, MD (2) · Robert Yarchoan, M.D. (2) · Abhijit P. Limaye, MD (1) · Adam Lerner, M.D. (1) · Akshjot Puri, M.D. (1) · Albert Park, MD (1) · Alexander T Maskin, MD (1) · Ann CT Vossen, Dr. (1) · Anna Wald, MD, MPH (1) · Anne Marie Oudesluys-Murphy, Prof. Dr. (1)
PMID 38700045, PMID 39807668, PMID 20353469, PMID 37530631, PMID 16780548, PMID 17640310, PMID 18039954, PMID 19632953, PMID 19738014, PMID 20547904, PMID 21487108, PMID 21502083, PMID 22694733, PMID 22694755, PMID 23009139, PMID 23196955, PMID 23404447, PMID 23418272, PMID 23593305, PMID 23959519, PMID 24078428, PMID 24174627, PMID 24224707, PMID 24256396, PMID 24656016, PMID 24983306, PMID 25331113, PMID 25560711, PMID 25661673, PMID 25738669, PMID 26416517, PMID 28383392, PMID 28437539, PMID 29166336, PMID 31420397, PMID 31862739, PMID 32276276, PMID 32286644, PMID 32493198, PMID 32504089, PMID 32726431, PMID 33720337, PMID 33740394, PMID 33811823, PMID 33861738, PMID 34864943, PMID 35076931, PMID 35194187, PMID 35761406, PMID 36724434
2015 (3), 2019 (2), 2005 (1), 2017 (1), 2018 (1), 2023 (1), P30AI027763 (1), R01AI184205 (1), R34AI095135 (1), U01AI110658 (1), U01DC014706 (1), UG1EY036344 (1)